Guardant, a biotechnology company, provides a blood test on Guardant’s Smart Liquid Biopsy platform that uses epigenomic analysis to detect circulating tumor DNA to predict GI cancer recurrence, according to a Jan. 21 news release.
The Guardant Reveal test is now covered by Medicare for use in the CRC surveillance setting after curative intent treatment. Previously, coverage expanded only to testing for CRC in the early post-surgical setting.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.